Q-linea

About Us

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Links

Q-linea

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

YEAR-END REPORT 1 JANUARY–31 DECEMBER 2018

Thu, Feb 14, 2019 07:30 CET

Successful capital raise and IPO on Nasdaq StockholmQuarter: October–December 2018 · Net sales amounted to SEK 0.3 million (1.5). · Operating result totalled SEK -39.0 million (-21.8). · The company reported a loss after tax of SEK -39.4 million (-21.9). · Earnings per share amounted to SEK -2.33 (-1.90). · Cash flow from operating activities totalled SEK -37.4 million (-21.1). Period: 1 January–31 December 2018 · Net sales amounted to SEK 1.1 million (1.5). · Operating result totalled SEK -127.4 million (-67.9). · The company reported a loss after tax of SEK -

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

YEAR-END REPORT 1 JANUARY–31 DECEMBER 2018